VACC

Investor Moves

Name	Value	Action	Change	Price	Current Price
Jim SimonsRenaissance Technologies $-82.9K ExitQ4 2025 $83k -- --
Jim SimonsRenaissance Technologies $49.1K AddQ3 2025 $49k -- --
Jim SimonsRenaissance Technologies $-962 TrimQ2 2025 $962 -- --
Jim SimonsRenaissance Technologies $-7.7K TrimQ1 2025 $7.7k -- --
Jim SimonsRenaissance Technologies $9.2K AddQ4 2024 $9.2k -- --
Ken GriffinCitadel Advisors $11.6K AddQ3 2024 $12k -- --

Trade VACC

About Vaccitech plc

Vaccitech plc is a clinical-stage biopharmaceutical company focused on developing cutting-edge T-cell immunotherapeutics and vaccines. Their mission is to treat and prevent a variety of infectious diseases and cancers. The company's therapeutic pipeline includes several programs undergoing clinical evaluation: VTP-300 is in Phase 1/2a clinical trials for chronic hepatitis B. VTP-200 is also in Phase 1/2a development, targeting human papillomavirus (HPV) infection. VTP-850 is progressing through Phase 1/2 clinical studies for prostate cancer. VTP-600 is engaged in Phase 1/2a trials for non-small cell lung cancer. In terms of prevention, their prophylactic initiatives feature: VTP-400, which is in a preclinical stage, designed to combat herpes zoster (shingles). VTP-500, which has concluded Phase 1 clinical trials for Middle East respiratory syndrome (MERS). Notably, Vaxzevria, a preventive vaccine against COVID-19 infection, is also part of their offerings. Established in 2016, the company was originally named Vaccitech Rx Limited before adopting its current name, Vaccitech plc, in March 2021. Vaccitech plc is headquartered in Oxford, United Kingdom.

CEO: William J. Enright MBA
IPO Date: Apr 30, 2021

Market Data

Open: $4.60
High: $5.09
Low: $4.39
Volume: 163.1K
Avg Volume: 719K
52W High: $5.10
52W Low: $1.64

Valuation

Market Cap: $193M
Enterprise Value: $-29M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-48M
Revenue: $0
Net Income: $-66M
Cash: $70M
Debt: $11M

Events

EarningsApr 30

actual -0.14